SBIR/STTR Research Award

REGULATION OF STEROID HORMONES BY OXIDOREDUCTASES

Award identifier 926fede6fda9e6693aaac97c4eae949ccc952a2dd0936b197f0f643230d2b3a8Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$185,910

Program and phase

SBIR · Phase I

Award year

2005

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Altoris, Inc.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2005-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Sex steroids play important roles in a number of cancers including breast, ovarian, endometrial and prostate cancers. In this proposal, we are planning to investigate means to modulate steroid levels in an effort to suppress tumor growth. During the Phase I of this proposal we will design inhibitors for 17beta-dehydrogenase, the enzyme that catalyzes the last step of 17beta-estradiol biosynthesis. There is strong literature evidence that modulation of this biosynthetic pathway is an effective treatment strategy, particularly for estrogen sensitive breast cancers. Small molecule inhibitors will be developed as potential clinical candidates and as biological probes to further study the pharmacological effects of inhibiting enzymes involved in the biosynthesis of 17beta-estradiol, a key steroid involved in the stimulation of breast cancer cell growth. The workplan is composed of four steps: 1) the structure guided design of inhibitors for this enzyme; 2) selection, synthesis and characterization potential inhibitors; 3) enzymological evaluation of the ligands; 4) evaluation of promising inhibitors in cellular assays. During the Phase I we plan to demonstrate that selective inhibitors can be designed for this enzyme using structure guided design starting from the structure of the endogenous ligand. In the process we will generate a small library of compounds that can be used as probes to study their effect on other steroid sensitive cancers. The second phase of these studies will evaluate the compounds in ex-vivo and in-vivo studies, with the ultimate purpose of identifying candidates for drug development.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.